Hims & Hers Health shares gain almost 4% after global expansion boosts revenue growth

Traders Union
All News
Stocks
Hims & hers health rises 3.89% today

Highlights

Hims & Hers Health international revenue rose over 17 times year-over-year to $131 million, with a target of surpassing $600 million by 2026.
The company faces investigations by the FTC for alleged medical data sharing and a separate board investigation into possible fiduciary breaches.
Shares of Hims & Hers Health are trading near session highs, with intraday volatility at 12.88% and an expected five-session range of $30.39 to $34.21.

Revenue ambitions rise amid FTC probe and global expansion moves

Hims & Hers Health reported that international revenue increased over 17 times year-over-year to $131 million, driven in part by the Eucalyptus acquisition and recent entry into new global markets. The company has outlined an ambitious target of surpassing $600 million in international revenue by 2026. Hims & Hers Health is also under investigation by the FTC for allegedly sharing customer medical data with third-party advertisers, with an additional board investigation underway regarding possible fiduciary breaches.

Anton Kharitonov, expert at Traders Union, notes the strong price move in Hims & Hers Health but remains cautious. He highlights the alarming FTC investigation into data privacy and additional board scrutiny, raising concerns about governance risks. While the technical uptrend is clear, Kharitonov warns that overbought signals and strong sell momentum on the MACD could foreshadow reversal. The company’s target for international growth appears ambitious yet highly dependent on restoring investor trust. "Until regulatory and board concerns are addressed, I view any upside as potentially unsustainable and consider downside risks elevated."

Viktoras Karapetjanc, expert at Traders Union, sees the dramatic increase in international revenue as a sign of strong long-term potential. He finds the company's global expansion and $600 million target impressive, noting that the bullish structure remains intact above key moving averages. Karapetjanc points to institutional interest likely driven by robust growth and ambitious forecasts. He emphasizes that, despite short-term regulatory noise, market confidence should drive further gains if revenue momentum continues. "I expect HIMS to consolidate before breaking higher as its growth story attracts more investors."

Parshwa Turakhiya, analyst, observes mixed sentiment for HIMS as traders react to both stellar revenue growth and ongoing investigations. He notes current volatility and sharp intraday recovery, with technical indicators signaling a risk of short-term pullback from overbought conditions. Turakhiya sees opportunity in tactical range trading as the stock navigates between $30.39 support and $34.21 resistance. "Momentum setups could play both ways here, so I’d watch for breakout confirmation before taking directional bets."

Mixed momentum as stock holds above technical support levels

The stock is trading above its 20-day, 50-day, and 200-day moving averages ($29.62, $31.86, and $29.01 respectively), confirming support for the uptrend across all periods and a bullish longer-term structure. Immediate resistance is at $34.21, while $31.86 acts as nearby support. The Ichimoku Kijun at $30.97 provides further underlying support. Momentum indicators are mixed: the MACD shows strong sell mode and waning momentum, the ADX remains neutral, RSI is just above 50 in buy territory, and both Stochastic RSI and Bull/Bear Power indicate overbought conditions. The CCI and Awesome Oscillator are neutral. Price action reflects strong intraday recovery with volatility at 12.88%.

Earlier, analysts noted that Hims & Hers Health had transitioned into a period of strong technical momentum following prior legal uncertainties. This latest update adds a significant operational growth dimension, with international expansion reinforcing the uptrend, but traders should monitor the $30.39 and $34.21 levels for signs of a potential breakout or renewed downside risk.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.